Warren Hosseinion, president of Nutex Health Inc. (NASDAQ:NUTX), reported a personal purchase of company stock on March 19, 2026. According to the filing, he acquired 252 shares at a per-share price of $94.0723, representing a total outlay of $23,706.
The purchase comes while Nutex Health shares were trading at $93.16. The stock is down 46% year-to-date but remains 53% higher than its price a year earlier.
Following the March 19 transaction, Hosseinion holds 7,765 shares of Nutex Health common stock directly. The company’s Form 4 filing also included a correction related to an earlier entry dated March 10, 2026, noting that Hosseinion exercised 3,656 Restricted Stock Units.
An analysis from InvestingPro cited in the filing materials indicates the stock appears undervalued at current levels and notes that the platform provides Fair Value estimates along with 10 additional ProTips for investors assessing the healthcare company.
Separately, Nutex Health reported a marked decline in total revenue for the fourth quarter of 2025. The company’s revenue fell 41.1% compared with the same quarter a year earlier. That quarterly drop has drawn investor attention despite the company’s stronger performance over the full 2025 fiscal year.
Analysts have not issued any upgrades or downgrades in response to the quarterly results, according to the information provided. Market reaction and analyst coverage appear limited in the immediate aftermath of the earnings announcement.
The Form 4 correction, the insider purchase, and the quarterly revenue decline are the primary items disclosed in the filings and related reports. Each disclosure provides concrete, company-sourced data points investors can use when evaluating Nutex Health’s near-term outlook and valuation.
Summary - The company’s president purchased 252 shares for $23,706 on March 19, 2026, while shares trade below year-ago peaks; a previous filing was corrected to show the exercise of 3,656 Restricted Stock Units; Nutex Health posted a 41.1% revenue decline in Q4 2025 and has not prompted analyst coverage changes.